These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 34088507)

  • 1. Optimising HPV vaccination communication to adolescents: A discrete choice experiment.
    Chyderiotis S; Sicsic J; Raude J; Bonmarin I; Jeanleboeuf F; Le Duc Banaszuk AS; Gauchet A; Bruel S; Michel M; Giraudeau B; Thilly N; Mueller JE
    Vaccine; 2021 Jun; 39(29):3916-3925. PubMed ID: 34088507
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Optimizing Communication on HPV Vaccination to Parents of 11- to 14-Year-Old Adolescents in France: A Discrete Choice Experiment.
    Chyderiotis S; Sicsic J; Gagneux-Brunon A; Raude J; Barret AS; Bruel S; Gauchet A; Le Duc Banaszuk AS; Michel M; Giraudeau B; Thilly N; Mueller JE;
    Patient; 2024 Sep; 17(5):575-588. PubMed ID: 38693318
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Parental preferences for HPV vaccination in junior middle school girls in China: A discrete choice experiment.
    Zhu S; Chang J; Hayat K; Li P; Ji W; Fang Y
    Vaccine; 2020 Dec; 38(52):8310-8317. PubMed ID: 33223307
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Quantifying preferences around vaccination against frequent, mild disease with risk for vulnerable persons: A discrete choice experiment among French hospital health care workers.
    Godinot LD; Sicsic J; Lachatre M; Bouvet E; Abiteboul D; Rouveix E; Pellissier G; Raude J; Mueller JE
    Vaccine; 2021 Jan; 39(5):805-814. PubMed ID: 33419603
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Quantifying population preferences around vaccination against severe but rare diseases: A conjoint analysis among French university students, 2016.
    Seanehia J; Treibich C; Holmberg C; Müller-Nordhorn J; Casin V; Raude J; Mueller JE
    Vaccine; 2017 May; 35(20):2676-2684. PubMed ID: 28408120
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Public health impact and cost-effectiveness of a nine-valent gender-neutral HPV vaccination program in France.
    Majed L; Bresse X; El Mouaddin N; Schmidt A; Daniels VJ; Pavelyev A; Levy-Bachelot L; Elbasha E
    Vaccine; 2021 Jan; 39(2):438-446. PubMed ID: 33261895
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Implementation of a human papillomavirus vaccination demonstration project in Malawi: successes and challenges.
    Msyamboza KP; Mwagomba BM; Valle M; Chiumia H; Phiri T
    BMC Public Health; 2017 Jun; 17(1):599. PubMed ID: 28651574
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Quadrivalent Human Papillomavirus Vaccine: Recommendations of the Advisory Committee on Immunization Practices (ACIP).
    Markowitz LE; Dunne EF; Saraiya M; Lawson HW; Chesson H; Unger ER; ;
    MMWR Recomm Rep; 2007 Mar; 56(RR-2):1-24. PubMed ID: 17380109
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Misinformation Drives Low Human Papillomavirus Vaccination Coverage in South African Girls Attending Private Schools.
    Milondzo T; Meyer JC; Dochez C; Burnett RJ
    Front Public Health; 2021; 9():598625. PubMed ID: 33681125
    [No Abstract]   [Full Text] [Related]  

  • 10. Incremental cost-effectiveness evaluation of vaccinating girls against cervical cancer pre- and post-sexual debut in Belgium.
    Demarteau N; Van Kriekinge G; Simon P
    Vaccine; 2013 Aug; 31(37):3962-71. PubMed ID: 23777952
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness of HPV vaccination in the context of high cervical cancer incidence and low screening coverage.
    Võrno T; Lutsar K; Uusküla A; Padrik L; Raud T; Reile R; Nahkur O; Kiivet RA
    Vaccine; 2017 Nov; 35(46):6329-6335. PubMed ID: 28899625
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Implementation of a national school-based Human Papillomavirus (HPV) vaccine campaign in Fiji: knowledge, vaccine acceptability and information needs of parents.
    La Vincente SF; Mielnik D; Jenkins K; Bingwor F; Volavola L; Marshall H; Druavesi P; Russell FM; Lokuge K; Mulholland EK
    BMC Public Health; 2015 Dec; 15():1257. PubMed ID: 26684658
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Facilitators and barriers of human papillomavirus vaccine uptake in young females 18-26 years old in Singapore: A qualitative study.
    Lim ASE; Lim RBT
    Vaccine; 2019 Sep; 37(41):6030-6038. PubMed ID: 31473002
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Asking about human papillomavirus vaccination and the usefulness of registry validation: a study of young women recruited using Facebook.
    Gunasekaran B; Jayasinghe Y; Brotherton JM; Fenner Y; Moore EE; Wark JD; Fletcher A; Tabrizi SN; Garland SM
    Vaccine; 2015 Feb; 33(6):826-31. PubMed ID: 25444782
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Stated preferences for human papillomavirus vaccination for adolescents in selected communities in Ibadan, Southwest Nigeria: A discrete choice experiment.
    Balogun FM; Omotade OO; Svensson M
    Hum Vaccin Immunother; 2022 Nov; 18(6):2124091. PubMed ID: 36383765
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Modelling the population-level impact of vaccination on the transmission of human papillomavirus type 16 in Australia.
    Regan DG; Philp DJ; Hocking JS; Law MG
    Sex Health; 2007 Sep; 4(3):147-63. PubMed ID: 17931528
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The value of male human papillomavirus vaccination in preventing cervical cancer and genital warts in a low-resource setting.
    Sharma M; Sy S; Kim JJ
    BJOG; 2016 May; 123(6):917-26. PubMed ID: 26176301
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Human Papilloma Virus Vaccination Among Female Patients Attending French Pediatric Cystic Fibrosis Centers.
    Rousset-Jablonski C; Haesebaert J; Denis A; Reix P; Llerena C; Perceval M; Touzet S; Durieu I
    J Pediatr Adolesc Gynecol; 2021 Jun; 34(3):317-323. PubMed ID: 33338628
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Girls' preferences for HPV vaccination: a discrete choice experiment.
    de Bekker-Grob EW; Hofman R; Donkers B; van Ballegooijen M; Helmerhorst TJ; Raat H; Korfage IJ
    Vaccine; 2010 Sep; 28(41):6692-7. PubMed ID: 20708696
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Estimation of mid-and long-term benefits and hypothetical risk of Guillain-Barre syndrome after human papillomavirus vaccination among boys in France: A simulation study.
    Duong CH; Mueller JE; Tubert-Bitter P; Escolano S
    Vaccine; 2022 Jan; 40(2):359-363. PubMed ID: 34865876
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.